This strategic acquisition highlights Calibre Scientific's dedication to broadening its range of products and services for customers within the DACH region.
During the last 35 years, RUWAG has served the Swiss market across the broader diagnostics space with expertise in infectious diseases, gastroenterology, oncology, autoimmune and microbiology.
The company also provides life sciences products including transfection, cells, media, test kits, gene expression systems and endotoxin testing.
In addition, RUWAG supplements its product expertise with its integrated customer service and support capability by providing maintenance and repair services for instrumentation, along with its in-house testing lab.
The RUWAG acquisition strengthens Calibre Scientific’s growing platform in Switzerland, a dynamic market for diagnostics and life sciences products given its prominent pharmaceutical industry.
“With deep technical product expertise and a complementary service offering, RUWAG has successfully catered to the Swiss market for more than three decades,” said Ben Travis, Chief Executive Officer at Calibre Scientific.
“The addition of RUWAG to the Calibre Scientific family is highly synergistic as it expands our product and service offering in the region and adds a variety of new supplier and customer relationships.”
“I am thrilled to embrace this new chapter in RUWAG’s history as we become part of the Calibre Scientific family of businesses,” said Daniel Rothenbühler, Managing Director of RUWAG.
“The portfolio expansion resulting from this integration empowers us to serve our esteemed customers with even greater excellence and precision.”
